Chidamide is the first oral subtype-selective HDACI (HDAC1,2,3,10) approved in China and the first HDACI of the benzamide class approved for treating relapsed and refractory PTCL 24. This evidence concerns the gene HDAC1 and mature T-cell and NK-cell non-Hodgkin lymphoma.